PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
A phase 3 trial of Gefurulimab in childhood cancers, run by Alexion Pharmaceuticals, Inc., now recruiting.
Overview
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT06607627 by Alexion Pharmaceuticals, Inc., with 12 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-15. Interventions recorded: Gefurulimab.
Similar pages
not linked directly; found by shared links- TrialOpen-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Shares Childhood cancers (all types) and the tag pipeline.
- TrialDurvalumab and Tremelimumab for Pediatric Malignancies
Shares Childhood cancers (all types), AstraZeneca and the tag pipeline.
- TrialEvaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Shares Childhood cancers (all types), AstraZeneca and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Childhood cancers (all types) and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca and the tag pipeline.
- TrialA Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Shares AstraZeneca and the tag pipeline.